Advertisement

SPD 502 (NS 1209), a New Selective AMPA Antagonist, Reduces the Infarct Size in Rats Following Permanent Occlusion of the Middle Cerebral Artery

  • T. N. Sager
  • A. Møller
  • F. Wätjen
  • O. B. Paulson
  • J. Drejer
Conference paper

Abstract

Alpha-amino-3-hydroxy-5-methyl-4-isoxazoleproprionate (AMPA)-antagonists (i.e., 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline [NBQX] and 6-(1-imidazolyl)-7-nitroquinoxaline-2,3(1H,4H)-dione [YM900]) have shown protective effects in different animal models of focal and global cerebral ischemia. We have developed a new highly selective and water-soluble AMPA antagonist (SPD 502). The compound is well-tolerated in rodents producing no liver or kidney pathology after doses up to 120 mg/kg. The aim of the present study was to evaluate whether SPD 502 was also neuroprotective in a focal cerebral ischemia model.

Keywords

Cerebral Ischemia Middle Cerebral Artery Middle Cerebral Artery Occlusion Infarct Volume Global Cerebral Ischemia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • T. N. Sager
  • A. Møller
  • F. Wätjen
  • O. B. Paulson
  • J. Drejer

There are no affiliations available

Personalised recommendations